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ABSTRACT The hepatitis C virus (HCV) glycoprotein E2 is the major target of neu-
tralizing antibodies and is therefore highly relevant for vaccine design. Its structure
features a central immunoglobulin (Ig)-like -sandwich that contributes to the bind-
ing site for the cellular receptor CD81. We show that a synthetic peptide corre-
sponding to a -strand of this Ig-like domain forms an -helix in complex with the
anti-E2 antibody DAO5, demonstrating an inside-out flip of hydrophobic residues
and a secondary structure change in the composite CD81 binding site. A detailed in-
teraction analysis of DAO5 and cross-competing neutralizing antibodies with soluble
E2 revealed that the Ig-like domain is trapped by different antibodies in at least two
distinct conformations. DAO5 specifically captures retrovirus particles bearing HCV
glycoproteins (HCVpp) and infectious cell culture-derived HCV particles (HCVcc). In-
fection of cells by DAO5-captured HCVpp can be blocked by a cross-competing neu-
tralizing antibody, indicating that a single virus particle simultaneously displays E2
molecules in more than one conformation on its surface. Such conformational plas-
ticity of the HCV E2 receptor binding site has important implications for immunogen
design.
IMPORTANCE Recent advances in the treatment of hepatitis C virus (HCV) infection
with direct-acting antiviral drugs have enabled the control of this major human
pathogen. However, due to their high costs and limited accessibility in combination
with the lack of awareness of the mostly asymptomatic infection, there is an un-
changed urgent need for an effective vaccine. The viral glycoprotein E2 contains re-
gions that are crucial for virus entry into the host cell, and antibodies that bind to
these regions can neutralize infection. One of the major targets of neutralizing anti-
bodies is the central immunoglobulin (Ig)-like domain within E2. We show here that
this Ig-like domain is conformationally flexible at the surface of infectious HCV particles
and pseudoparticles. Our study provides novel insights into the interactions of HCV E2
with the humoral immune system that should aid future vaccine development.
KEYWORDS CD81 binding site, hepatitis C virus, Ig-like domain, conformational
flexibility, glycoprotein E2, monoclonal antibodies, vaccine design
Hepatitis C virus (HCV) has infected an estimated 170 million people worldwide, andthe majority of infected individuals develop chronic infection that leads to pro-
gressive liver disease (1). The recently approved combination therapies involving
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direct-acting antivirals have impressive cure rates (99%) (2), but their high costs limit
accessibility, and so there is still an urgent medical need to develop a preventative HCV
vaccine.
Most neutralizing antibodies (nAbs) identified to date target the viral envelope
glycoprotein E2 (3), which interacts with the cellular receptors CD81 (4) and scavenger
receptor BI (SR-BI) (5). E2 contains several hypervariable regions (6, 7) that can be
deleted without affecting the overall glycoprotein conformation (8). Crystallization of
E2 was a difficult endeavor, and crystal structures were reported only recently, via use
of truncated versions of the E2 ectodomain (cE2), which lack some of these hypervari-
able regions and the C terminus, in complex with anti-E2 antibody fragments (9, 10).
These difficulties suggested that HCV E2 is more flexible than glycoproteins of other
viruses that have been successfully crystallized on their own. Further evidence for the
flexibility of the HCV glycoproteins comes from the observations that the oligomeric
status as well as the disulfide connectivity of the HCV glycoproteins fluctuate during the
HCV replication cycle (11, 12).
The two available cE2 structures revealed a central immunoglobulin (Ig)-like domain
that is completed by random coil, small helices, and an additional -sheet perpendic-
ular to the Ig -sandwich (Fig. 1A). The exposed C=-E loop of this -sandwich, also called
CD81 binding loop, comprises amino acid (aa) residues 519 to 535 (the amino acid
numbering used here corresponds to the polyprotein of the HCV genotype 1a strain
H77) and constitutes, together with two segments that are distant in the primary
structure (aa 412 to 423 and aa 428 to 446), the composite CD81 binding site (10, 13,
14) (Fig. 1A and B). The CD81 binding loop is stabilized by binding of a Fab fragment
in one of the two E2 structures (10) with the side chain of residues F537 and L539 located
on -strand E buried in the hydrophobic core of the Ig-like domain. However, in the
second E2 structure, residues 524 to 535 are disordered and the side chain of F537 is
solvent exposed (9), indicating that -strand E is partially unfolded and the Ig-like
domain can adopt more than one conformation in the absence of a stabilizing Fab
fragment. The fact that the disulfide connectivity in the two reported cE2 structures
differs in one disulfide bond (9, 10) further highlights the extensive conformational
flexibility of HCV E2, which in many respects behaves differently than other viral
glycoproteins by not adopting a single, rigid conformation.
Further insights into the structural organization of neutralizing epitopes within E2
came from cocrystallization of Fab fragments derived from nAbs in complex with their
respective epitope peptides comprising E2 residues 412 to 423 or 430 to 446 (15–20).
More recent structural studies using different antibodies in complex with similar
epitope peptides revealed that these epitopes are either conformationally flexible
(residues 412 to 423 [21–23]) or at least adopt two discrete conformations (residues 430
to 446 [24]). Moreover, electron microscopy analysis illustrated the flexibility of aa 412
to 423 as a neutralizing Fab targeting this segment bound soluble E2 from a variety of
different angles of approach (25).
Here, we provide further evidence that the receptor binding part of the Ig-like
-sandwich within E2 can adopt distinct conformations at the surface of infectious
particles (both virus particles bearing HCV glycoproteins [HCVpp] and infectious cell
culture-derived HCV particles [HCVcc]), exposing residues that are part of the hydro-
phobic core and changing the secondary structure of one -strand. We used two
monoclonal antibodies (MAbs) that share contact residues but recognize distinct
conformations of the Ig-like domain to detect the simultaneous presence of distinct
protein conformations at the surface of a single HCVpp. Our results demonstrate that
the previously described structural flexibility within HCV E2 extends beyond the
composite CD81 binding site and also that the Ig-like domain undergoes conforma-
tional rearrangements. This report therefore provides novel structural insights into the
conformational flexibility of receptor binding sites present in viral glycoproteins in
general, and in particular of HCV E2, with implications for vaccine design.
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RESULTS AND DISCUSSION
Crystallization of antibody fragment-peptide complexes and structure deter-
mination. We generated and characterized anti-E2 MAb DAO5, which specifically
recognizes a linear epitope comprising part of the CD81 binding loop and the E strand
of the central -sandwich within HCV E2 (see Text S1 and Fig. S1 in the supplemental
material). The linear character of the DAO5 epitope makes it a useful tool for structural
analysis of this functionally important region.
We expressed a Fab and a single-chain Fv (scFv) fragment of MAb DAO5 in
Drosophila melanogaster S2 cells, as described elsewhere (26, 27). Diffraction-quality
crystals of these antibody fragments were obtained in complex with peptides spanning
E2 residues 529 to 540 of strains J4 (genotype 1b) and JFH-1 (genotype 2a) (see Text
FIG 1 Crystal structure of DAO5 in complex with its peptide epitope. (A) Cartoon representation of cE2
(PDB 4WMF). The N and C termini are indicated; the Ig-like domain and the perpendicular sheet are
highlighted in blue and cyan, respectively. The three segments contributing to the CD81 binding site are
colored as described for panel B. (B) Linear diagram of the E2 glycoprotein. N-linked glycosylation sites
are indicated above the diagram, and the three segments contributing to the composite CD81 binding
site are shown as colored boxes and labeled with their amino acid residue numbers. A bar corresponding
to the crystallized cE2 construct described in reference 10 is shown below the diagram, with the thinner
line indicating disordered regions. (C) View of the DAO5 paratope in complex with the JFH-1 peptide (aa
529 to 540). The molecular surfaces of the light chain and heavy chain are colored light gray and dark
gray, respectively, and the peptide is shown as a cartoon, displaying the side chains as sticks and colored
according to atom type (orange, red, and blue for carbon, oxygen, and nitrogen, respectively). The
-helix formed by the C-terminal end of the peptide contacts the heavy chain CDR loops, while its
N-terminal extended region (N532-T534) contacts the CDR loops of the light chain. (D) Electron density
of the composite omit map contoured at 1 around the peptide corresponding to HCV E2 strain JFH-1
(upper panel) or J4 (lower panel). The amino acid sequences of the peptides are displayed, with gray
residues indicating disordered regions. (E) Percentages of accessible surface area (ASA) buried in the
complex, calculated using PISA (51) and represented per residue as stacked columns for heavy (dark gray)
and light (light gray) chains. (F) RMSD upon superposition of the two peptides, created using Chimera
(52) and including all atoms (dark gray) or main chain atoms only (light gray) in the calculation and
represented per residue. (G) Average temperature factors of the peptides plotted per residue for
complexes with JFH-1 (light gray) and J4 (dark gray).
Structural Flexibility in the HCV E2 Ig-Like Domain ®
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S1). Three independent structures were determined by using the molecular replace-
ment method with the previously determined crystal structure of the unliganded scFv
fragments as the search model (scFv-J4 peptide, scFv-JFH1 peptide, and Fab-J4 pep-
tide). The final electron density maps revealed unambiguous density, allowing us to
build independent atomic models of the peptides (Fig. 1C and D). Superposition of
peptide residues 532 to 540 from Fab-J4 and scFv-J4 peptide complexes confirmed an
identical peptide conformation with a root mean square deviation (RMSD) of 0.136 Å,
calculated over the backbone atoms (Fig. 1F), which together with the unrelated crystal
packing interfaces for the Fab and scFv complexes indicated that our crystal structures
reflected the genuine conformation of the polypeptide chain recognized by MAb
DAO5. In view of the similarity of the individual complex structures (two complexes per
asymmetric unit [AU] in the scFv complexes and one complex per AU in the Fab
complex), we selected for further analysis those with the lowest mean temperature
factor (B-factor) comprising residues 532 to 540 (Fig. 1G) (indicating the highest degree
of order). Since the interactions of the two peptides with the paratope are almost
identical, we will discuss the common molecular binding determinants and highlight
differences only where necessary.
Molecular determinants of DAO5 binding. Unexpectedly, the peptide forms one
-helical turn comprising residues 535 to 539 (DVM/FLL), in stark contrast to the
extended conformation observed in the cE2 structure (10). The peptide interaction with
the paratope buries an area of ~730 Å2 on the peptide and ~650 Å2 on the antibody,
with a total buried surface area of 1,379 Å2 and a shape complementarity index of 0.801
and 0.774 for the J4 and JFH-1 peptides, respectively, similar to other antibody-antigen
complexes (28, 29). The B-factor and RMSD analyses indicated a stable and strong
interaction with the paratope, with a higher degree of disorder toward the peptide
termini (Fig. 1F and G). Of note, this segment contains two asparagine residues N532
and N540 that are glycosylated in the context of the viral particle (30). Our peptide
structures show that the side chains of both asparagines are exposed in the complex
and therefore able to accommodate these two N-linked glycans (Fig. S2). Interactions
between the DAO5 MAb and the glycosylated protein are thus likely to be unaffected
by the presence of the glycans, similar to the interactions with the peptide.
Residues N532-T534 interact exclusively with the light chain, forming an N-terminal
contact region. The -helical turn of the peptide with residues M/F537, L538, and L539
establishes mainly hydrophobic side chain interactions, predominantly with the heavy
chain, forming a second contact region at the C terminus of the peptide. Both side
chain oxygen atoms of D535 form hydrogen bonds with the hydroxyl group of YL32,
highlighting D535 as an essential contact residue for DAO5 binding, whereas in the E2
structure it forms hydrogen bonds to the side chains of T534 and T526 and also to the
main chain NH group of N532 and G530, thereby dominating the main chain conforma-
tion in this particular region. V536 does not interact with the paratope, suggesting that
the interaction of D535 with YL32 is required to form a junction connecting the two
separate (N- and C-terminal) contact regions, thereby stabilizing their relative positions.
A detailed comparison of peptide residues 532 to 540 with the corresponding
segment in the cE2 structure revealed that the short -helix observed in complex with
DAO5 folds as strand E of the -sandwich in cE2 (Fig. 2A to C). The distance spanned
by residues 532 to 540 is considerably shorter in the peptide structure than in cE2
(20.6 Å and 11.6 Å, respectively) (Fig. 2D). In the context of E2, this difference between
the two conformations can likely be accommodated, because this segment is encom-
passed at either side by the putatively flexible C=-E and E-F loops (Fig. 2E). In the
presence of nAb AR3C, the side chains of F537 and L539 are oriented toward the
hydrophobic core of the -sandwich (red side chains in Fig. 2E) (10), whereas both
residues are buried to more than 80% in the DAO5 binding interface (Fig. 1E), indicating
that they need to be solvent exposed to allow interaction with DAO5 (Fig. 2F). Of note,
in the absence of a stabilizing neutralizing Fab fragment bound at this surface, the side
chain of F537 is also solvent exposed (9). These results indicate that strand E is not only
Vasiliauskaite et al. ®
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able to switch secondary structure upon binding of a specific antibody, but also that
side chains can flip inside-out, suggesting that they are not stably anchored in the
hydrophobic core of the Ig-like domain. In view of DAO5 binding to the soluble E2
ectodomain as well as infectious HCVpp and HCVcc particles (see below), we can
therefore conclude that the Ig-like domain within HCV E2 can accommodate confor-
mational rearrangements to allow for the conversion between a closed conformation
and a putative open conformation. In the closed conformation, residues 536 to 538
form -strand E (Fig. 2E), whereas the putative open conformation allows these
residues to be recognized in the form of a short -helix (Fig. 2F), with the side chains
of F537 and L539 being accessible for interaction with the antibody. The high degree of
sequence conservation within this region (Fig. 2B) suggests that this conformational
flexibility reflects an intrinsic property of HCV E2, in line with the previously reported
experimental evidence for the structural flexibility of E2 in the context of a soluble
ectodomain and infectious viral particles (11, 12, 21–24).
The Ig-like domain within soluble E2 adopts more than one conformation. To
exclude that DAO5 recognizes an artificial denatured form of soluble E2 (sE2), we
analyzed the overall conformation of a DAO5 scFv-sE2412-715 complex by pulldown
assay using a Fab fragment derived from a conformation-sensitive human MAb, CBH-
FIG 2 Conformation of the HCV E2 peptide aa 532 to 540. (A and C) Residues 532 to 540 of the extended
conformation observed in the context of cE2 (PDB 4MWF) (A) and the helical conformation observed in
the DAO5/peptide complex (C) are shown as cartoons, with the side chains shown as sticks and colored
according to atom type (orange and red for oxygen and nitrogen, respectively). Carbon atoms are ramp
colored from the N terminus (blue) to the C terminus (red) through green and yellow. cE2 is shown in
gray. (B) Secondary structure elements taken from the crystal structures are shown above and below an
amino acid alignment of the polypeptide segments from strains H77 and JFH-1. (D) C trace of the two
backbone conformations colored as described for panel A. The extended conformation in the context of
cE2 spans 20.6 Å (left panel), and the helical conformation spans 11.6 Å (right panel). (E and F) Schematic
representation of the Ig-like domain within HCV E2 as observed in the E2 core fragment in the presence
of a stabilizing Fab fragment (E) (PDB 4MWF) and in a putative open conformation (F) in which residues
F537 and L539 (side chains are shown as red sticks) are solvent exposed, allowing for interaction with MAb
DAO5, similar to the conformation of F537 observed in the second E2c structure (PDB 4NX3).
Structural Flexibility in the HCV E2 Ig-Like Domain ®
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4D, which recognizes a non-overlapping epitope outside the CD81 binding site (31). A
ternary complex consisting of DAO5 scFv, sE2412-715, and CBH-4D Fab was observed,
suggesting that the overall fold of sE2412-715 was not affected (Fig. 3A, left panel)
despite the rearrangement within the Ig-like domain.
To determine the local conformation of the CD81 binding loop, we first tested if the
DAO5 Fab-sE2 complex could interact with the soluble large extracellular loop (LEL) of
CD81. Purified DAO5 Fab-sE2 complex or sE2 alone was incubated with a molar excess
of CD81-LEL, and then the mixture was subjected to size exclusion chromatography
(SEC). SDS-PAGE analysis of the peak fractions showed that the purified DAO5 Fab-sE2
complex, unlike sE2 alone, failed to bind CD81 (Fig. 3A, right panel). A more detailed
analysis was performed by mixing a prepurified complex of sE2412-715–DAO5 Fab
individually with Fab fragments derived from several well-characterized human and
murine broadly neutralizing nAbs (bnAbs) to assess cross-competition. Ternary complex
formation was analyzed by SEC. We observed a shift of the peak from a binary DAO5
Fab-sE2412-715 complex to that from a ternary complex incorporating Fab AP33 (which
recognizes E2 aa 412 to 423 [32]), indicating, as expected, no cross-competition
FIG 3 Cross-competition profile of DAO5. (A) Cross-competition and biochemical analysis of the
sE2412-715–DAO5 complex. (Left) sE2412-715 and an sE2412-715–DAO5 scFv complex were affinity loaded
onto a StrepTactin column, a CBH-4D Fab fragment was added, and the eluted complex was analyzed by
SDS-PAGE under nonreducing conditions. (Right) CD81-LEL was incubated overnight at RT with the
full-length HCV ectodomain (comprising residues 384 to 715; sE2) and the sE2-DAO5 Fab complex,
followed by SEC and analysis of the peak fractions by SDS-PAGE under reducing conditions. DAO5 heavy
and light chains form an apparent single band in the reducing gel due to an almost identical molecular
mass of ~24 kDa. (B) A preformed sE2412-715–DAO5 Fab complex was incubated in the absence or
presence of a Fab fragment targeting a non-overlapping (AP33) or overlapping (e137) region of cE2 and
analyzed by SEC. After preincubation with AP33 (green), appearance of a peak at a higher molecular mass
indicated ternary complex formation; after preincubation with e137 Fab (blue), the presence of peaks
corresponding to the binary complex (at ~13 ml) and an isolated Fab fragment (at ~16 ml) showed that
no ternary complex was formed. (C) Cross-competition profile of the sE2412-715–DAO5 Fab complex,
obtained by SEC analysis as described for panel B, with a panel of Fab fragments derived from the
indicated well-characterized anti-E2 MAbs. (D) sE2384-713 produced in human cells (eE2) was incubated
with DAO5 Fab, and then the complex as well as the individual components were analyzed by SEC. The
presence of a peak at a higher molecular mass indicated binary complex formation (12 ml, blue). A
considerable protein fraction eluted in peaks corresponding to uncomplexed eE2 (green) and DAO5 Fab
(red).
Vasiliauskaite et al. ®
May/June 2017 Volume 8 Issue 3 e00382-17 mbio.asm.org 6
 
m
bio.asm
.org
 o
n
 M
ay 30, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
between AP33 and DAO5 (Fig. 3B). In contrast, mixing a preformed binary DAO5
Fab-sE2412-715 complex with the Fab fragment of the human bnAb e137, which targets
the CD81 binding loop (33), resulted in the appearance of a lower-molecular-weight
peak that corresponded to an isolated Fab fragment (Fig. 3B, blue). This indicated that
no ternary complex formation is possible due to cross-competition. Similarly, we
observed no ternary complex with Fab fragments from A8, HC84.1, CBH-23, CBH-7, or
HC-1 (Fig. 3C), suggesting that DAO5 directly cross-competes with most bnAbs target-
ing the CD81 binding site.
Despite directly competing with both CD81-LEL and bnAbs targeting the CD81
binding site, DAO5 Fab surprisingly lacks neutralizing activity (Fig. S1C). Numerous
MAbs targeting the CD81 binding loop have been characterized, and many of them
cluster in one of two groups, being either (i) MAbs from human patients that recognize
conformation-sensitive epitopes and potently neutralize HCV infection (e.g., MAbs A8
[34], e137 [33], AR3C [35], CBH-5 [36], and HC-1 [37]) (reviewed in reference 3) or (ii)
rodent MAbs that recognize mostly linear epitopes in the N-terminal half of the CD81
binding loop and neutralize HCV infection to a lesser extent or not at all (e.g., 3E5 [38],
9/75 and 2/64a [39], H77.31, J6.27 [40], 19D8, 21C3, 23G2, and 21D9 [41], or 1H8 [42]).
These results suggest a positive correlation between a conformation-sensitive character
and a neutralizing activity of antibodies directed against the CD81 binding loop and
indicate that antibodies recognizing linear epitopes within this region neutralize HCV
infection less potently.
We analyzed in more detail the competition of DAO5 with bnAbs targeting the CD81
binding site, using bnAb e137 as an example. Although no ternary complex comprising
sE2, e137 Fab, and DAO5 Fab was observed, fragments of both antibodies bound to
sE2412-715 molecules immobilized on a StrepTactin column (Fig. 4A), in apparent
contradiction with the SEC results presented in Fig. 3B. It is important to note, however,
FIG 4 Evidence for more than one conformation of the CD81 binding loop. (A to C) sE2412-715 or sE2 was
immobilized on a StrepTactin column and incubated first with a molar excess of DAO5 scFv and
subsequently with e137 (A), AR3C (B), or A8 Fab (C). Eluted complexes were analyzed by SDS-PAGE. (D
and E) Real-time SPR analysis of Fab binding to immobilized sE2 recorded the binding response (in
resonance units [RU]) as a function of time. Fab fragments of e137 (D) and DAO5 (E) were injected over
a surface with immobilized HCV sE2. After reaching equilibrium between association and dissociation, a
second Fab fragment (either the same Fab again or the alternative one) or a buffer control was injected.
Structural Flexibility in the HCV E2 Ig-Like Domain ®
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that SEC reveals whether a single glycoprotein molecule is able to bind both antibody
fragments simultaneously, whereas the StrepTactin column pulldown assay investi-
gates whether a glycoprotein solution contains both molecules recognized by DAO5
and other molecules recognized by e137. Similarly, immobilized sE2 molecules pulled
down fragments of both DAO5 and AR3C (Fig. 4B), as well as DAO5 and A8 (Fig. 4C).
These results suggest that the Ig-like domain in soluble E2 can be present in more than
one conformation and therefore be recognized either by DAO5 or by one of the human
bnAbs.
Although several non-overlapping conformation-dependent antibodies recognize
sE2 produced in insect cells (43), a crystal structure of this protein has not yet been
reported. In order to exclude a specific conformation of the insect cell-derived protein,
we produced sE2384-713 in human cells (eE2) as described before (9) and mixed it with
DAO5 Fab overnight at 4°C. SEC analysis revealed a peak corresponding to a DAO5
Fab-eE2 complex (Fig. 3D), demonstrating that the majority of eE2 adopts the putative
open conformation in the Ig-like domain. The fact that a considerable fraction of eE2
did not form a complex with DAO5 Fab (Fig. 3D) supports the notion that the Ig-like
domain in eE2 can also adopt more than one conformation recognized by DAO5 and
putatively by AR3C/e137, respectively, similar to the insect-cell derived sE2.
To further analyze this conformational flexibility, we performed surface plasmon
resonance (SPR) experiments, in which we injected two Fabs consecutively over im-
mobilized sE2 (Fig. 4D and E). Nearly equal signals resulted from binding of e137 Fab
(Fig. 4D) and DAO5 Fab (Fig. 4E), indicating that comparable numbers of immobilized
sE2 molecules were recognized by either Fab. After reaching an equilibrium between
association and dissociation of the first Fab, a repeated injection of the same Fab did
not lead to a further increase in binding, indicating that saturation was reached after
the first injection. In contrast, injection of the second Fab resulted in markedly in-
creased binding to sE2, supporting the hypothesis that sE2 in more than one confor-
mation was immobilized. After binding of the second Fab, the total amount of bound
Fab reached similar levels, regardless of which Fab was bound first. The fact that DAO5
recognizes E1E2 complex expressed in HEK cells (Fig. S1A and B) and a soluble E2
ectodomain expressed in either insect or mammalian cells with a similar binding
efficiency suggests that the conformational flexibility in the Ig-like domain is indepen-
dent of the presence of HVR1 and the expression/host type.
More than one conformation of E2 is present simultaneously on the surface of
infectious HCV particles. The most sensitive way to detect interactions between nAbs
and virus particles is to measure neutralization rather than direct protein-protein
interactions. This was not possible with MAb DAO5, as it is a non-neutralizing antibody.
Nevertheless, given that all experiments described so far were carried out using a
soluble ectodomain of E2, it was crucial to demonstrate that more than one confor-
mation is found in the functional full-length E1E2 glycoprotein complex at the virus
surface. We therefore tested whether DAO5 MAb binds to the retrovirus-based HCV
pseudoparticles (HCVpp) displaying genotype 2a JFH1 E1E2. DAO5 MAb was immobi-
lized on Immuno tubes and incubated with the luciferase reporter HCVpp, and then the
captured particles were tested for infectivity and E2 content. We found that DAO5
specifically captured full-length E2 incorporated into infectious HCVpp, demonstrating
that its epitope was displayed at the surface of these particles (Fig. 5A). To investigate
whether more than one conformation of E2 is present simultaneously at the virus
surface, we tested the neutralization of immobilized particles by using the cross-
competing e137 Fab. Our results showed that the particles captured by the DAO5 MAb
were efficiently neutralized by e137 Fab in a concentration-dependent manner (Fig. 5B),
suggesting that more than one conformation of the Ig-like domain is simultaneously
present on the surface of the same HCVpp.
A key experiment investigated whether the DAO5 epitope can also be detected at
the surface of infectious cell culture-derived particles (HCVcc). It has been reported that
antibodies targeting the viral glycoproteins do not efficiently bind HCVcc (44). How-
ever, modified immunocapture experiments using HCVcc revealed that DAO5 specifi-
Vasiliauskaite et al. ®
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cally captured full-length E2 (Fig. 5C, lower panel). In addition, immunocapture of
HCVcc using DAO5 resulted in ~15% infected cells, whereas immunocapture using a
control antibody only yielded ~4% infected cells (Fig. 5C, upper panel), demonstrating
that the DAO5 epitope is displayed at the surface of infectious HCVcc. These data
support the notion that the Ig-like domain within functional full-length E1E2 glycopro-
tein complexes can adopt either conformation at the surface of infectious virus
particles.
DISCUSSION
In this study, we found that an important part of the CD81 binding site within the
HCV glycoprotein E2, the CD81 binding loop, adopts more than one distinct confor-
FIG 5 More than one conformation of the Ig-like domain was observed on both HCVpp and HCVcc
infectious particles. (A) Concentrated HCVpp were immunocaptured using Immuno tubes. After remov-
ing unbound material, the captured particles were analyzed by SDS-PAGE, followed by immunoblotting
to detect E2 (lower panel). The presence of captured infectious HCVpp was determined by overnight
incubation with Huh7 cells in suspension. The cells were then transferred into tissue culture dishes, and
infectivity levels were determined 48 h later by measuring luciferase activity, shown as relative light units
(RLU) (upper panel). (B) DAO5-captured particles were incubated with Huh7 cells as described for panel
A in the presence of e137 Fab or control anti-bovine viral diarrhea virus (BVDV) E2 Fab at the indicated
concentrations. Infectivity levels were determined as described above and are shown as the percent
infectivity in the absence of Fab. (C) Concentrated HCVcc were immunocaptured as described for panel
A. After removing unbound material, captured particles were analyzed by SDS-PAGE followed by
immunoblotting to detect E2 (lower panel). The presence of captured infectious HCVcc was determined
by overnight incubation with Huh7 cells in suspension. The cells were then transferred into tissue culture
dishes, and the number of infected cells was determined after 72 h by flow cytometry after labeling with
anti-NS5A MAb 9E10 (upper panel). Experiments were performed at least in triplicate, and results shown
are means  standard deviations. The P values (panel A and C) were calculated using an unpaired t test.
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mation at the surface of both HCVpp and HCVcc. One of these conformations has been
observed in complex with the human bnAb AR3C (10); insights into another one are
provided by our crystal structure of MAb DAO5 in complex with an epitope peptide.
This murine MAb was derived from immunization with a soluble E2 ectodomain
produced in insect cells that binds several conformation-sensitive antibodies (43) and
elicits broadly neutralizing, conformation-sensitive antibodies (45). Biochemical analy-
ses demonstrated that three human bnAbs bind to a conformation that is different
from the open conformation recognized by DAO5. It thus appears that the majority of
bnAbs target a closed conformation of the Ig-like domain with particular relevance for
the “receptor binding” step during virus entry, although further structural studies are
required to investigate this hypothesis.
Of note, HCV envelope glycoprotein complexes at the virus surface are not readily
accessible to antibodies, either due to their low abundance or occlusion by host-
derived lipoproteins (44). Our results indicate that functional full-length E1E2 glyco-
protein complexes can be trapped in two different conformations at the surface of
HCVpp and HCVcc particles by MAbs DAO5 and e137, with residues that are part of the
hydrophobic core in one conformation being solvent exposed in the second confor-
mation. A similar structural promiscuity has been described for the AB loop of tear
lipocalin, a lipid binding protein in tears (46), and in this context it is tempting to
speculate whether the exposure of hydrophobic side chains in E2 is related to a
putative lipid binding function and the extensive association of HCV virions with host
lipoproteins.
The observed structural differences within the Ig-like domain of HCV E2 are striking
(Fig. 2E and F) and further illustrate how structurally flexible this molecule is. Our results
extend the previously described notion that segments involved in the CD81 binding
site are conformationally flexible (21, 24, 25). Remarkably, not only was the interaction
site within E2 shown to be structurally flexible, but also marked conformational
fluctuations were demonstrated for the region within the CD81-LEL, which is thought
to interact with E2 (47). This observation, together with the above-mentioned structural
flexibilities in the CD81 binding site, suggests that the currently available structures of
E2 might not provide an accurate view of its conformation when bound to CD81. It is
likely that binding of a given CD81 binding loop conformation to nAbs correlates with
its binding to CD81, and the fact that the putative open conformation is not recognized
by nAbs suggests that it does not bind to CD81. However, a high-resolution structure
of E2 in complex with CD81 is required to understand the molecular determinants of
this interaction.
The fact that DAO5 does not neutralize HCV infection despite the demonstrated
cross-competition with CD81 binding implies that within the virus envelope the protein
cannot be converted from one conformation to the other. This suggests that during
virion assembly both conformations are incorporated into the virus envelope, and it
raises the question why a receptor binding glycoprotein like HCV E2 is so conforma-
tionally flexible, i.e., how can the virus benefit from displaying a receptor binding site
in different conformations? One possibility is that the helical conformation of the Ig-like
domain serves as a decoy that distracts the host immune system from the relevant,
receptor binding conformation. In this context, it will be interesting to investigate
whether antibodies recognizing the helical conformation of the CD81 binding loop are
present in patient serum, e.g., by using an epitope scaffold carrying a conformation-
restricted DAO5 epitope.
The described flexibility also suggests that a structure-guided stabilization of the
Ig-like domain within E2, e.g., by engineering additional disulfide bonds, can potentially
improve the capacity of E2 to induce neutralizing antibodies by eliminating conversion
to a particular conformer. Our results therefore provide novel insights regarding the
interplay between E2 and the host humoral immune response, and understanding this
interplay will greatly aid the rational design of an effective HCV vaccine.
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MATERIALS AND METHODS
Antibodies. The mouse MAb DAO5 was generated and its epitope mapped as described in Text S1.
Purified DAO5 IgG was labeled with biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinide ester (BAC-
SulfoNHS) using the BiotinTag Micro biotinylation kit (Sigma).
Retrovirus-based HCV pseudoparticles. Human epithelial kidney cells (HEK-293T; ATCC CRL-1573)
and human hepatoma Huh7 cells were propagated as reported previously (48). HCVpp were generated
in HEK-293T cells (49). Virus particles were filtered through 0.45-m-pore-size membrane and concen-
trated 10-fold using Amicon Ultra-15 centrifugal units with a 100,000 molecular weight cutoff membrane.
Huh7 cells were infected with MAb DAO5-captured HCVpp as described below.
Immunocapture of infectious HCV particles (HCVpp/HCVcc). Nunc Immuno tubes were coated
with 40 g/ml MAb DAO5 IgG or mouse IgG control (M-9035; Sigma) in phosphate-buffered saline (PBS)
overnight, blocked with PBS containing 5 to 10% fetal calf serum for 3 h at room temperature, and then
rinsed thoroughly with PBS. Concentrated HCVpp or concentrated HCVcc of infectious HCV strain JFH-1
was added to the tubes and incubated for at least 3 h at room temperature (RT). Unbound material was
removed by rinsing thoroughly with PBS, and the immunocaptured material was analyzed as follows.
First, to test for infectivity, 1  105 Huh7 cells were added to each tube and incubated overnight at
37°C. The human hepatoma cell line Huh7 was a kind gift from Jean Dubuisson and has been described
previously (48). The cells were then seeded into a 12-well cell culture plate and incubated for a further
48 h (for HCVpp) or 72 h (HCVcc). To determine HCVpp infectivity, cells were lysed and luciferase activity
was measured using Bright Glo (Promega). To test for neutralization, the immunocaptured HCVpps were
preincubated with e137 and control Fabs in cell culture medium for 1 h before adding cells. To determine
HCVcc infectivity, cells were detached using cell dissociation buffer (Sigma), fixed with 2% formaldehyde
for 20 min, washed with PBS, and then permeabilized with PBS containing 0.1% saponin (Sigma) for
30 min on ice. After washing with PBS containing 0.02% Tween 20 (PBS-T; Sigma), the cells were
incubated on ice for 1 h with the anti-HCV NS5A MAb 9E10 (a kind gift of Charles M. Rice) or an irrelevant
isotype control IgG, washed with PBS-T, and then incubated further with Alexa Fluor 488 donkey
anti-mouse IgG HL. Following washing with PBS-T, the stained cells were resuspended in PBS and
analyzed by flow cytometry on a Guava EasyCyte HT cell sorter (Merck Millipore), and virus infectivity was
measured as the percentage of infected cells.
Next, to test for HCV E2 content, proteins were stripped from the Nunc Immuno tubes by adding
Laemmli sample buffer containing -mercaptoethanol and heating at 100°C for 3 min. Proteins were
separated by 10% SDS-PAGE, followed by immunoblotting for HCV E2 with biotinylated MAb DAO5 and
a streptavidin-horseradish peroxidase.
Ethics statement. The mouse experiments were approved by the University of Glasgow Ethical
Review Process and were conducted following guidelines from the National Centre for the Replacement,
Refinement and Reduction of Animals in Research (NC3R) under project license 60/3657 granted by the
UK Home Office Animals (Scientific Procedures) Act 1986.
Recombinant proteins, complex formation, crystallization, and structure determination. The
generation and purification of recombinant DAO5 Fab or scFv and the HCV E2 soluble ectodomains (sE2)
produced in insect cells as well as crystallization, data collection, processing, structure determination, and
analysis are described in detail in Text S1 in the supplemental material. The mammalian HCV E2
ectodomain (residues 384 to 713) was produced in HEK 293 cells as described before (9). Space groups
and cell dimensions of the crystals, resolution limits, data collection details, and refinement statistics are
summarized in Table S1.
Cross-competition analysis of antibody fragments and CD81 by SEC sE2 or sE2412-715 were mixed
together with DAO5 Fab for 16 h at 30°C to allow for complex formation, and the complex was
subsequently purified by SEC. For Fab cross-competition analysis, a second Fab was added to the purified
complex for 16 h at 4°C, followed by a second SEC analysis on a Superdex 200 10/300 column. Soluble
CD81-LEL was produced as described elsewhere (50). One hundred micrograms of sE2 or purified
sE2-DAO5 Fab complex was mixed with a molar excess of CD81-LEL overnight at 23°C, followed by SEC
analysis on a Superdex 200 10/300 column. Peak fractions were concentrated and analyzed by SDS-PAGE
under nonreducing conditions. followed by Coomassie blue staining.
Pulldown assay of antibody fragments using a soluble E2 ectodomain. For pulldown assays,
sE2412-715 containing a Strep tag was used. The sE2412-715–DAO5 Fab or sE2412-715–DAO5 scFv complexes
were purified as described above, bound to a StrepTactin superflow minicolumn, and washed with 10
column volumes followed by addition of a molar excess of CBH-4D Fab and another washing step. To
analyze cross-competition between e137, AR3C, and DAO5 antibody fragments, sE2 or sE2412-715 was
bound to a StrepTactin Superflow minicolumn and washed with 10 column volumes, followed by
addition of the first antibody fragment (from which the Strep tag had been proteolytically removed),
washing, addition of the second antibody fragment (also lacking the Strep tag), and another washing
step. Complexes were eluted, and all fractions were analyzed by SDS-PAGE followed by Coomassie blue
staining.
Surface plasmon resonance analysis. SPR experiments were performed in triplicate on a Biacore
T200 system (GE Healthcare, Uppsala, Sweden), equilibrated at 25°C in PBS (pH 7.4) complemented with
0.01% Tween 20, using a CM5 sensor chip with a density of around 13,000 response units (RU; similar to
measurement in picrograms per square millimeter) and anti-Strep antibody (C23.21) immobilized
through amide bonds.
sE2412-715 (5 g/ml) was captured on the chip via its Strep tag at a density of 2,100 to 2,200 RU. The
DAO5 or e137 Fabs (50 g/ml) were then injected for 5 min, followed by buffer, DAO5, or e137. The Fab
signal monitored on an anti-Strep reference surface was subtracted.
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Accession number(s). The atomic coordinates and structure factors for three structures have been
deposited in the Protein Data Bank (http://www.pdb.org/) under accession numbers 5NPH (Fab/J4), 5NPI
(scFv/J4), and 5NPJ (scFv/JFH).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00382-17.
TEXT S1, DOCX file, 0.05 MB.
FIG S1, TIF file, 0.7 MB.
FIG S2, TIF file, 1.1 MB.
TABLE S1, DOCX file, 0.1 MB.
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